Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Vaccine source : Ir.vaccinex.com save search
Vaccinex, Inc. Announces Upcoming Presentation at the 2022 American Association for Cancer Research Meeting Updating the Phase 1b Segment of the KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA (pembrolizumab) in Patients with Recurrent or Meta
Published: 2022-03-09 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 1.83%
H: 18.92%
C: 17.12%
america ema phase 1b research presentation pepinemab phase 1 keytruda dating cancer vaccine phase 2b
Vaccinex Announces $6.6 Million Private Placement
Published: 2022-01-27 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 14.75%
H: 8.57%
C: 7.62%
ces vaccine
Vaccinex, Inc. to Present at the Clinical Trials on Alzheimer’s Disease (CTAD) Meeting
Published: 2021-11-09 (Crawled : 00:20) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -0.51%
H: 5.08%
C: 4.06%
disease alzheimer clinical trials vaccine trials trial alzheimer’s alzheimer's disease alzheimer's
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer’s (SITC) 36th Annual Meeting
Published: 2021-11-10 (Crawled : 16:20) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -1.46%
H: 3.47%
C: -1.49%
immunotherapy therapy cancer vaccine
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
Published: 2021-11-04 (Crawled : 16:00) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -0.65%
H: 3.5%
C: -0.77%
vaccine conference
Vaccinex to Present at the Virtual Huntington’s Study Group Meeting on November 4-6, 2021
Published: 2021-11-01 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -2.09%
H: 6.18%
C: 3.21%
huntington vaccine
Vaccinex to Chair Panel Q&A Session and Present Poster at the XV European Meeting on Glial Cells in Health and Disease
Published: 2021-06-30 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 0.37%
H: 3.66%
C: 2.56%
disease europe vaccine
Vaccinex Announces Activation of Clinical Sites to Enroll Patients in Studies of Pepinemab as Single Agent in Alzheimer’s Disease and in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (HNSCC)
Published: 2021-06-08 (Crawled : 11:00) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 4.0%
H: 0.64%
C: -5.77%
disease alzheimer vaccine keytruda pepinemab enroll alzheimer’s alzheimer's disease alzheimer's cell carcinoma
Vaccinex to Present at the Jefferies 2021 Virtual Healthcare Conference
Published: 2021-05-19 (Crawled : 12:00) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -5.44%
H: 6.68%
C: 3.9%
vaccine conference presentation
Vaccinex Announces Publication of Results from CLASSICAL-Lung Phase 1b/2 Clinical Trial in Non-Small Cell Lung Cancer in the Peer-Reviewed Journal Clinical Cancer Research
Published: 2021-04-21 (Crawled : 12:15) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 1.72%
H: 7.2%
C: 5.51%
lung cancer phase 1 results cancer vaccine research trial phase 1b phase 2b
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
Published: 2021-03-16 (Crawled : 12:00) - ir.vaccinex.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.26%
H: 0.04%
C: -0.33%
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 7.81%
H: 8.13%
C: -5.16%
financial results results vaccine
Vaccinex to Present at the Oppenheimer 31st Annual Healthcare Conference
Published: 2021-03-11 (Crawled : 13:06) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 2.27%
H: 5.4%
C: 5.08%
vaccine conference presentation
Vaccinex Reports Second Quarter 2020 Financial Results and Provides Corporate Update
Published: 2020-08-14 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 2.37%
H: 14.77%
C: 9.25%
financial results results vaccine
Vaccinex Announces Appointment of Robert Scala as Chief Commercial Officer
Published: 2020-08-27 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: -1.16%
H: 6.64%
C: -0.59%
vaccine commercialization
Vaccinex Announces Clinical Collaboration with Merck to Evaluate Pepinemab in Combination with KEYTRUDA® in Advanced, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma
Published: 2020-09-17 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 14.56%
H: 9.08%
C: -2.15%
collaboration vaccine keytruda pepinemab cell carcinoma
Vaccinex, Inc. to Present at the Virtual Investor KOL Roundtable
Published: 2020-10-26 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 6.91%
H: 2.99%
C: -0.5%
vaccine presentation
Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
Published: 2020-10-29 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 1.67%
H: 2.29%
C: -3.28%
huntington vaccine
CORRECTION -- Vaccinex to Present Additional SIGNAL Data at Huntington Study Group 2020 Medical Conference
Published: 2020-10-29 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 1.67%
H: 2.29%
C: -3.28%
huntington vaccine
Vaccinex Reports Third Quarter 2020 Financial Results and Provides Corporate Update
Published: 2020-11-13 (Crawled : 14:12) - ir.vaccinex.com
VCNX | $4.8 -2.76% 7.9K
|
Health Technology
|
| O: 5.56%
H: 4.31%
C: -4.78%
financial results results vaccine
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
WLGS | $0.59 18.0% 17.9% 2.3M
|
NYC 4 | $5.91 -4.83% 14.38% 770
|
Finance
MGOL 4 | $0.229 -4.18% 13.72% 420K
|
GBR | $1.42 31.48% 11.27% 990K
|
Energy Minerals
BQ | $0.269 1.51% 11.15% 1.1M
|
Consumer Non-Durables
DEO | News | $140.76 -0.02% 8.27% 560K
|
Consumer Non-Durables
KUKE | $2.88 2.49% 7.64% 360K
|
MGLD 4 | $1.23 8.85% 7.32% 14K
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.